Data from HER-2/neu Mediates Oncogenic Transformation via Altered CREB Expression and Function

Abstract

<div>Abstract<p>The cyclic (c)AMP responsive element binding protein (CREB) plays a key role in many cellular processes, including differentiation, proliferation, and signal transduction. Furthermore, CREB overexpression was found in tumors of distinct origin and evidence suggests an association with tumorigenicity. To establish a mechanistic link between HER-2/neu–mediated transformation and CREB protein expression and function, <i>in vitro</i> models of HER-2/neu–overexpressing and HER-2/neu–negative/silenced counterparts as well as human mammary carcinoma lesions with defined HER-2/neu status were used. HER-2/neu overexpression resulted in the induction and activation of CREB protein <i>in vitro</i> and <i>in vivo</i>, whereas short hairpin RNA (shRNA)–mediated inhibition of HER-2/neu correlated with downregulated CREB activity. CREB activation in HER-2/neu–transformed cells enhanced distinct signal transduction pathways, whereas their inhibition negatively interfered with CREB expression and/or activation. CREB downregulation in HER-2/neu–transformed cells by shRNA and by the inhibitors KG-501 and lapatinib caused morphologic changes, reduced cell proliferation with G<sub>0</sub>–G<sub>1</sub> cell-cycle arrest, which was rescued by CREB expression. This was accompanied by reduced cell migration, wound healing, an increased fibronectin adherence, invasion, and matrix metalloproteinase expression. <i>In vivo</i> shCREB-HER-2/neu<sup>+</sup> cells, but not control cells, exerted a significantly decreased tumorgenicity that was associated with decreased proliferative capacity, enhanced apoptosis, and increased frequency of T lymphocytes in peripheral blood mononuclear cells. Thus, CREB plays an important role in the HER-2/neu–mediated transformation by altering <i>in vitro</i> and <i>in vivo</i> growth characteristics.</p><p><b>Implications:</b> These data suggest that CREB affects tumor immunogenicity and is a potential target for cancer therapy. <i>Mol Cancer Res; 11(11); 1462–77. ©2013 AACR</i>.</p></div>